Spark gene therapy improves vision, at least in short term: FDA

(Reuters) – Spark Therapeutics Inc’s experimental gene therapy for a rare inherited form of blindness improves vision, though it is unclear whether the benefit lasts over time, according to a preliminary review by the U.S. Food and Drug Administration.

Source: Reuters Health News